National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Rapid Review

Commenced Completed Outcome
23/12/2011 04/01/2012 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
May 2012  03/09/2012 Reimbursement not recommended at the submitted price

The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication

Vemurafenib (Zelboraf®) Summary

September 2014

The HSE has approved reimbursement following confidential price negotiations.